Navigation Links
Developing a Safer and More Effective Way to Deliver Rabies Antibodies
Date:2/5/2009

INCHEON, South Korea, Feb. 5 /PRNewswire/ -- The Centers for Disease Control and Prevention (CDC) and Celltrion, Inc., a South Korean biopharmaceutical company, have signed a Letter of Intent to permit joint research on the development of novel antibodies to protect people exposed to the rabies virus.

Medical attention for a person exposed to rabies is a two-step procedure. First, rabies immune globulin (RIG) is given to provide immediate antibodies neutralizing the rabies virus. Thereafter, the patient receives five doses of vaccine to build active immunity against the rabies virus.

Active immunity is detectable after the first week of vaccination so RIG is essential at the first stage of medical attention before a person develops their own antibodies from vaccine.

There are currently two types of RIG: human and equine. Human RIG can sometimes be in short supply due to manufacturing restrictions. It is expensive, and there are regulatory concerns because it comes from human blood. Because equine RIG is derived from horses, there are concerns that it may not provide the proper antibody response, and there are international animal care and use issues because of the involvement of horses in its production. In developing countries, where the majority of human rabies cases occur, both types of RIG are frequently unavailable.

The CDC/Celltrion collaboration addresses these problems by using cell culture to manufacture RIG of a new generation, which is expected to be safer, more effective and affordable.

"The CDC is excited to begin a novel research collaboration with Celltrion on the development of additional products that can provide immunity to rabies. We believe this effort holds great public health promise toward the prevention of this deadly disease, especially in developing countries," said Charles E. Rupprecht, V.M.D., chief of the CDC's Rabies Program.

Rabies is a viral disease of mammals which is transmitted through the bite of infected animals. The virus infects the central nervous system, causing inflammation of the brain and ultimately death, if medical assistance is not sought promptly after the exposure to prevent the disease. Rabies is particularly prevalent in Eastern Europe, Asia, South America, and Africa. An estimated 40,000 to 70,000 people die of the disease each year, mainly in Asia and Africa.

About Celltrion: Celltrion, established in 2002, is a contract manufacturing organization with its headquarters in Incheon, South Korea. Celltrion, an emerging leader in the biopharmaceutical industry, is dedicated to providing high quality services to accelerate product development, while offering scalable manufacturing capabilities for our clients and business partners. Celltrion is also investing in research and development of its own products in order to develop into a fully integrated biotechnology company. For more information, please visit Celltrion's website at http://www.celltrion.com.

     For additional information, please contact:
     Seung-Suh (Stanley) Hong, Ph.D.
     Senior Vice President, Business Development
     Celltrion, Inc. (USA)
     E-mail:  seungsuh.hong@celltrion.com
     Tel:  +1-650-766-2307

This press release contains forward-looking statements that involve risks and uncertainties. The forward-looking statements contained herein represent the judgment of Celltrion as of the date of this release. These forward- looking statements are no guarantees for future performance, and the forward- looking events discussed in this press release may not occur. Celltrion disclaims any intent or obligation to update any of these forward-looking statements.


'/>"/>
SOURCE Celltrion, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
2. DuPont, Genencor International and Tate & Lyle Honored for Groundbreaking Work in Developing Bio-PDO(TM)
3. International Atomic Energy Agency and National Foundation for Cancer Research Launch Major Initiative to Improve Cancer Prevention and Treatments in Developing Countries
4. Free CME-certified Webcast: Making Your Case: Up-to-date Answers for Developing Trends in PCI
5. The Diabetes Series 2008: Experts Speak About Developing Diabetes Therapeutics
6. Microchip Biotechnologies, Inc. Collaborating With Stanford University on Developing a Front End Microfluidic-Based Sample Preparation System for Pyrosequencing Platforms
7. Allen Institute for Brain Science Launches Three New Landmark Atlas Projects Focusing on the Human Brain, Developing Brain and Spinal Cord
8. Genetic Engineering & Biotechnology News reports on clinical trials in developing countries
9. Iowa State researchers developing system to efficiently convert biomass to ethanol
10. Pharmaceuticals & Biotechs to Share Insights for Developing Leaders in a Fast-Paced, Competitive Industry
11. Developing Sales Leaders: Benchmarks Reveal Tactics that Will Propel Your Business
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Calif. , June 23, 2016  Blueprint Bio, ... biological discoveries to the medical community, has closed its ... Matthew Nunez . "We have received ... with the capital we need to meet our current ... essentially provide us the runway to complete validation on ...
(Date:6/23/2016)... 23, 2016 On Wednesday, June 22, ... down 0.22%; the Dow Jones Industrial Average edged 0.27% lower ... 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage on the following ... Therapeutics (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... BIND ). Learn more about these stocks by accessing ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance Associates® ... provides a free webinar on Performing Quality Investigations: Getting to Root ... CT at no charge. , Incomplete investigations are still a major concern to ...
(Date:6/23/2016)...  Amgen (NASDAQ: AMGN ) today announced ... life sciences incubator to accelerate the development of new ... at QB3@953 was created to help high-potential life science ... early stage organizations - access to laboratory infrastructure. ... two "Amgen Golden Ticket" awards, providing each winner with ...
Breaking Biology Technology:
(Date:4/19/2016)... The new GEZE SecuLogic access ... "all-in-one" system solution for all door components. It can ... door interface with integration authorization management system, and thus ... minimal dimensions of the access control and the optimum ... offer considerable freedom of design with regard to the ...
(Date:4/14/2016)... April 14, 2016 BioCatch ... Detection, today announced the appointment of Eyal Goldwerger ... role. Goldwerger,s leadership appointment comes at a ... of the deployment of its platform at several of ... technology, which discerns unique cognitive and physiological factors, is ...
(Date:3/31/2016)...  Genomics firm Nabsys has completed a financial  restructuring ... , M.D., who returned to the company in October ... team, including Chief Technology Officer, John Oliver , ... and Vice President of Software and Informatics, Michael ... Dr. Bready served as CEO of Nabsys from 2005-2014 ...
Breaking Biology News(10 mins):